169 related articles for article (PubMed ID: 35847495)
21. Adoptive CD8
Liu S; Liu H; Song X; Jiang A; Deng Y; Yang C; Sun D; Jiang K; Yang F; Zheng Y
Nanoscale; 2021 Oct; 13(37):15789-15803. PubMed ID: 34528979
[TBL] [Abstract][Full Text] [Related]
22. Enhancing Anti-PD-1/PD-L1 Immune Checkpoint Inhibitory Cancer Therapy by CD276-Targeted Photodynamic Ablation of Tumor Cells and Tumor Vasculature.
Bao R; Wang Y; Lai J; Zhu H; Zhao Y; Li S; Li N; Huang J; Yang Z; Wang F; Liu Z
Mol Pharm; 2019 Jan; 16(1):339-348. PubMed ID: 30452269
[TBL] [Abstract][Full Text] [Related]
23. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
24. Selectively targeting tumor-associated macrophages and tumor cells with polymeric micelles for enhanced cancer chemo-immunotherapy.
Wei X; Liu L; Li X; Wang Y; Guo X; Zhao J; Zhou S
J Control Release; 2019 Nov; 313():42-53. PubMed ID: 31629039
[TBL] [Abstract][Full Text] [Related]
25. Blood-Brain-Barrier-Penetrating Albumin Nanoparticles for Biomimetic Drug Delivery via Albumin-Binding Protein Pathways for Antiglioma Therapy.
Lin T; Zhao P; Jiang Y; Tang Y; Jin H; Pan Z; He H; Yang VC; Huang Y
ACS Nano; 2016 Nov; 10(11):9999-10012. PubMed ID: 27934069
[TBL] [Abstract][Full Text] [Related]
26. Local Targeting of NAD
Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H
Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997
[TBL] [Abstract][Full Text] [Related]
27. Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma.
Shirinbak S; Chan RY; Shahani S; Muthugounder S; Kennedy R; Hung LT; Fernandez GE; Hadjidaniel MD; Moghimi B; Sheard MA; Epstein AL; Fabbri M; Shimada H; Asgharzadeh S
Oncoimmunology; 2021 Jan; 10(1):1838140. PubMed ID: 33489468
[TBL] [Abstract][Full Text] [Related]
28. Tumor repolarization by an advanced liposomal drug delivery system provides a potent new approach for chemo-immunotherapy.
Ringgaard L; Melander F; Eliasen R; Henriksen JR; Jølck RI; Engel TB; Bak M; Fliedner FP; Kristensen K; Elema DR; Kjaer A; Hansen AE; Andresen TL
Sci Adv; 2020 Sep; 6(36):. PubMed ID: 32917608
[TBL] [Abstract][Full Text] [Related]
29. Dual-Targeted Lipid Nanotherapeutic Boost for Chemo-Immunotherapy of Cancer.
Yong SB; Ramishetti S; Goldsmith M; Diesendruck Y; Hazan-Halevy I; Chatterjee S; Somu Naidu G; Ezra A; Peer D
Adv Mater; 2022 Apr; 34(13):e2106350. PubMed ID: 35044699
[TBL] [Abstract][Full Text] [Related]
30. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity.
Lee WS; Yang H; Chon HJ; Kim C
Exp Mol Med; 2020 Sep; 52(9):1475-1485. PubMed ID: 32913278
[TBL] [Abstract][Full Text] [Related]
31. Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma.
Shima T; Shimoda M; Shigenobu T; Ohtsuka T; Nishimura T; Emoto K; Hayashi Y; Iwasaki T; Abe T; Asamura H; Kanai Y
Cancer Sci; 2020 Feb; 111(2):727-738. PubMed ID: 31821665
[TBL] [Abstract][Full Text] [Related]
32. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
33. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
34. WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape.
Lu C; Liu Z; Klement JD; Yang D; Merting AD; Poschel D; Albers T; Waller JL; Shi H; Liu K
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326167
[TBL] [Abstract][Full Text] [Related]
35. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
[TBL] [Abstract][Full Text] [Related]
36. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
[TBL] [Abstract][Full Text] [Related]
37. Regulatory T Cells Tailored with pH-Responsive Liposomes Shape an Immuno-Antitumor Milieu against Tumors.
Ou W; Jiang L; Gu Y; Soe ZC; Kim BK; Gautam M; Poudel K; Pham LM; Phung CD; Chang JH; Kim JR; Ku SK; Yong CS; Kim JO
ACS Appl Mater Interfaces; 2019 Oct; 11(40):36333-36346. PubMed ID: 31535550
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses.
Chen X; Pan X; Zhang W; Guo H; Cheng S; He Q; Yang B; Ding L
Acta Pharm Sin B; 2020 May; 10(5):723-733. PubMed ID: 32528824
[TBL] [Abstract][Full Text] [Related]
39. Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal.
Isoyama S; Mori S; Sugiyama D; Kojima Y; Tada Y; Shitara K; Hinohara K; Dan S; Nishikawa H
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446575
[TBL] [Abstract][Full Text] [Related]
40. Targeting tumor endothelial hyperglycolysis enhances immunotherapy through remodeling tumor microenvironment.
Shan Y; Ni Q; Zhang Q; Zhang M; Wei B; Cheng L; Zhong C; Wang X; Wang Q; Liu J; Zhang J; Wu J; Wang G; Zhou F
Acta Pharm Sin B; 2022 Apr; 12(4):1825-1839. PubMed ID: 35847509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
